Bradykinin B2 receptor antagonists
The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
1. A compound having the following structure:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 1 , and at least one carrier substance, excipient or adjuvant.
3. A method of treating angioedema in a subject comprising administering to the subject with angioedema a compound, or pharmaceutically acceptable salt thereof, according to claim 1 .
4. The method of claim 3 , wherein the angioedema is hereditary angioedema or drug induced angioedema.
5. A method of treating hereditary angioedema in a subject comprising administering to the subject with hereditary angioedema a pharmaceutical composition according to claim 2 .
6. The method of claim 5 , wherein the pharmaceutical composition is orally administered to the subject with hereditary angioedema.
7. A compound having the following structure:
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 7 , and at least one carrier substance, excipient or adjuvant.
9. A method of treating angioedema in a subject comprising administering to the subject with angioedema a compound, or pharmaceutically acceptable salt thereof, according to claim 7 .
10. The method of claim 9 , wherein the angioedema is hereditary angioedema or drug induced angioedema.
11. A method of treating hereditary angioedema in a subject comprising administering to the subject with hereditary angioedema a pharmaceutical composition, wherein the pharmaceutical composition comprises a compound having the following structure:
or a pharmaceutically acceptable salt thereof, and at least one carrier substance, excipient or adjuvant.
12. The method of claim 11 , wherein the pharmaceutical composition is orally administered to the subject with hereditary angioedema.